Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

ngs us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies.  Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units.  The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution.  Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study.  "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs).  ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs.  In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols.  In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 ... Interactive Customer Experience Association recognized 15 winners in ... mobile, as applied across multiple vertical markets. ... Healthcare Deployment Award for its success with ... ContextMedia:Health, the leading provider ...
(Date:7/28/2015)... -- For many medical institutions and universities, commercializing patented innovations ... be a constant challenge. Taking an idea all the ... A new company in Tampa ... Device Investments (MDI) was created to commercialize medical devices ... develops, manufactures and markets the products, with the intent ...
(Date:7/28/2015)... ALBANY, New York , July 28, 2015 ... of a new report, titled " Cancer Diagnostics ... Forecast, 2014 - 2020 " . According to this ... at a CAGR of 7.6% during the forecast period of ... was valued at US$100,994.5 million and is expected to be ...
Breaking Medicine Technology:ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4
... in Parts of Bucks, Delaware, Montgomery,Philadelphia Counties, ... the first night of aerial treatments, the Department ... to protect,the public against the mosquito-borne West Nile ... between 8 p.m. and,midnight in portions of Bucks, ...
... in Battle to Prevent ... Onset of Parkinson,s Disease, CHICAGO, Aug. 27 ... University of Nottingham,have made a crucial breakthrough in the battle to ... and Parkinson,s disease., The researchers have genetically produced the first ...
Cached Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... first two patients in a Clinical Performance Study for the Invisiport at Wheaton ... and 6 French catheter options, offers a less invasive, patient-friendly alternative to traditional ...
(Date:7/29/2015)... Palatine, IL (PRWEB) , ... July 29, 2015 , ... ... the ever-expanding population of children with autism, Little City took a proactive stance and ... and occupied. The Coleman Foundation grant provides valuable support to building the third home. ...
(Date:7/29/2015)... ... ... TransFlip is an all new dynamic transition pack for FCPX, containing flipping ... are easy to apply and modify for any skill-level user. TransFlip includes custom bounce ... kinetic flipping panel animations are just a few clicks away. , TransFlip contains over ...
(Date:7/29/2015)... St. Louis, MO (PRWEB) , ... July 29, 2015 , ... ... the website, the Talcum Powder Cancer Lawsuit Center. The website now features a page ... warnings, and news pieces from other sources. The Talcum Powder Lawsuit News ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran lawsuits ... Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling Zofran ... the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate and ...
Breaking Medicine News(10 mins):Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4
... Carry New Package, ATLANTA, March 25 White ... beverage for kids, announced today the launch of,three new ... natural,fruit-filled beverages. Shaw,s, ShopRite and Pathmark, new distribution,outlets in ... a host of leading,retailers to introduce the brand in ...
... in a cup, instead of bracing for a needle prick, ... major step in that direction is the cataloguing of the ... saliva, identified by a consortium of three research teams, according ... Research. Replacing blood draws with saliva tests promises to make ...
... CRH Medical Corporation,(CRM:TSX-V) announced today that it has opened ... is the Company,s first in the Miami area,one of ... The opening of,the Miami Center brings the Company,s total ... National Institute of Health, the prevalence rate of,hemorrhoids in ...
... March 25 Almost Family, Inc.,(Nasdaq: AFAM ) ... the,Medicare-certified home health agency owned by Apex Home Healthcare,Services, ... Company Comments on Combination, "We are very ... operations of Apex to our Company, and we are ...
... Sufferers Can Now Sleep Protected and at Ease With ... Asthma & Allergy Friendly(TM) Bedding, ... leading,manufacturer of innovative and premium home textile products, today,announced that ... allergy friendly(TM) by the Asthma and Allergy,Foundation of America (AAFA). ...
... more than income, where people live determines who goes out ... News) -- Your neighborhood may have a major influence on ... at data on 8,782 people in 373 Chicago neighborhoods. , ... higher levels of poverty, lower levels of education, and more ...
Cached Medicine News:Health News:White Hat Brands Takes Dog On It! Fortified Juice Beverage for Kids to New Heights 2Health News:Spit tests may soon replace many blood tests 2Health News:Spit tests may soon replace many blood tests 3Health News:CRH Medical Corporation opens new Center in Miami, Florida 2Health News:Almost Family Announces Acquisition of Apex Home Health 2Health News:Almost Family Announces Acquisition of Apex Home Health 3Health News:Almost Family Announces Acquisition of Apex Home Health 4Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 2Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 3Health News:Neighborhood Influences Exercise Levels 2
Direct assays, no sample extraction, hydrolysis or other pretreatment required. Highly specific antiserum, minimal cross-reactivity with estrone, estradiol and other estrogen metabolites....
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... presents the i.Series refrigerator ... solutions for the blood ... features than ever before, ... are at the forefront ...
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8590. Model 8590 is UL Listed, C...
Medicine Products: